{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,3,14]],"date-time":"2026-03-14T03:25:16Z","timestamp":1773458716248,"version":"3.50.1"},"reference-count":32,"publisher":"Galenos Yayinevi","issue":"4","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Jcrpe"],"DOI":"10.4274\/jcrpe.galenos.2022.2022-2-2","type":"journal-article","created":{"date-parts":[[2022,5,31]],"date-time":"2022-05-31T11:59:52Z","timestamp":1653998392000},"page":"393-401","source":"Crossref","is-referenced-by-count":3,"title":["The Assessment of the Hypothalamic-Pituitary-Adrenal Axis After Oncological Treatment in Pediatric Patients with Acute Lymphoblastic Leukemia"],"prefix":"10.4274","volume":"14","author":[{"given":"Barbara","family":"Hull","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Anna","family":"Wedrychowicz","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Magdalena","family":"Ossowska","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Aleksandra","family":"Furtak","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Joanna","family":"Badacz","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Szymon","family":"Skocze\u0144","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Jerzy B.","family":"Starzyk","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"2811","published-online":{"date-parts":[[2022,12,1]]},"reference":[{"key":"ref0","doi-asserted-by":"publisher","unstructured":"1. Ribera JM, Oriol A. Acute lymphoblastic leukemia in adolescents and young adults. Hematol Oncol Clin North Am 2009;23:1033-1042, vi.","DOI":"10.1016\/j.hoc.2009.07.002"},{"key":"ref1","unstructured":"2. Derwich K. Ostra bia\u0142aczka limfoblastyczna najcz\u0119stszy nowotw\u00f3r wieku dzieci\u0119cego. G\u0142os pacjenta onkologicznego 2020;1:10-11."},{"key":"ref2","doi-asserted-by":"publisher","unstructured":"3. Hunger SP, Lu X, Devidas M, Camitta BM, Gaynon PS, Winick NJ, Reaman GH, Carroll WL. Improved survival for children and adolescents with acute lymphoblastic leukemia between 1990 and 2005: a report from the children's oncology group. J Clin Oncol 2012;30:1663-1669. Epub 2012 Mar 12","DOI":"10.1200\/JCO.2011.37.8018"},{"key":"ref3","doi-asserted-by":"publisher","first-page":"6756","DOI":"10.1038\/s41598-020-63528-0","article-title":"Rates and trends of childhood acute lymphoblastic leukaemia: an epidemiology study","volume":"10","author":"Kakaje","year":"2020","unstructured":"4. Kakaje A, Alhalabi MM, Ghareeb A, Karam B, Mansour B, Zahra B, Hamdan O. Rates and trends of childhood acute lymphoblastic leukaemia: an epidemiology study. Sci Rep 2020;10:6756.","journal-title":"Sci Rep"},{"key":"ref4","doi-asserted-by":"publisher","unstructured":"5. Cooper SL, Brown PA. Treatment of pediatric acute lymphoblastic leukemia. Pediatr Clin North Am 2015;62:61-73. Epub 2014 Oct 18","DOI":"10.1016\/j.pcl.2014.09.006"},{"key":"ref5","doi-asserted-by":"publisher","first-page":"734","DOI":"10.1111\/j.1365-2141.2005.05509.x","article-title":"Benefit of dexamethasone compared with prednisolone for childhood acute lymphoblastic leukaemia: results of the UK Medical Research Council ALL97 randomized trial","volume":"129","author":"CD","year":"2005","unstructured":"6. Mitchell CD, Richards SM, Kinsey SE, Lilleyman J, Vora A, Eden TO; Medical Research Council Childhood Leukaemia Working Party. Benefit of dexamethasone compared with prednisolone for childhood acute lymphoblastic leukaemia: results of the UK Medical Research Council ALL97 randomized trial. Br J Haematol 2005;129:734-745.","journal-title":"Br J Haematol"},{"key":"ref6","doi-asserted-by":"publisher","first-page":"30","DOI":"10.1186\/1710-1492-9-30","article-title":"A practical guide to the monitoring and management of the complications of systemic corticosteroid therapy","volume":"9","author":"Liu","year":"2013","unstructured":"7. Liu D, Ahmet A, Ward L, Krishnamoorthy P, Mandelcorn ED, Leigh R, Brown JP, Cohen A, Kim H. A practical guide to the monitoring and management of the complications of systemic corticosteroid therapy. Allergy Asthma Clin Immunol 2013;9:30.","journal-title":"Allergy Asthma Clin Immunol"},{"key":"ref7","doi-asserted-by":"publisher","first-page":"542","DOI":"10.1016\/S0140-6736(99)06290-X","article-title":"Suppression and recovery of adrenal response after short-term, high-dose glucocorticoid treatment","volume":"355","author":"Henzen","year":"2000","unstructured":"8. Henzen C, Suter A, Lerch E, Urbinelli R, Schorno XH, Briner VA. Suppression and recovery of adrenal response after short-term, high-dose glucocorticoid treatment. Lancet 2000;355:542-545.","journal-title":"Lancet"},{"key":"ref8","doi-asserted-by":"publisher","first-page":"537","DOI":"10.1002\/pbc.21339","article-title":"Adrenal axis function after high-dose steroid therapy for childhood acute lymphoblastic leukemia","volume":"50","author":"Einaudi","year":"2008","unstructured":"9. Einaudi S, Bertorello N, Masera N, Farinasso L, Barisone E, Rizzari C, Corrias A, Villa A, Riva F, Saracco P, Pastore G. Adrenal axis function after high-dose steroid therapy for childhood acute lymphoblastic leukemia. Pediatr Blood Cancer 2008;50:537-541.","journal-title":"Pediatr Blood Cancer"},{"key":"ref9","doi-asserted-by":"publisher","unstructured":"10. Salem MA, Tantawy AA, El Sedfy HH, El Laboudy MA, Toaima DN, Mahmoud NH, Selim DM. A prospective study of the hypothalamic-pituitary-adrenal axis in children with acute lymphoblastic leukemia receiving chemotherapy. Hematology 2015;20:320-327. Epub 2014 Oct 16","DOI":"10.1179\/1607845414Y.0000000208"},{"key":"ref10","doi-asserted-by":"publisher","first-page":"736","DOI":"10.1016\/S0022-3476(04)00233-1","article-title":"Suppression of adrenal function in children with acute lymphoblastic leukemia following induction therapy with corticosteroid and other cytotoxic agents","volume":"144","author":"Mahachoklertwattana","year":"2004","unstructured":"11. Mahachoklertwattana P, Vilaiyuk S, Hongeng S, Okascharoen C. Suppression of adrenal function in children with acute lymphoblastic leukemia following induction therapy with corticosteroid and other cytotoxic agents. J Pediatr 2004;144:736-740.","journal-title":"J Pediatr"},{"key":"ref11","doi-asserted-by":"publisher","first-page":"21","DOI":"10.1067\/mpd.2000.107385","article-title":"Time course of recovery of adrenal function in children treated for leukemia","volume":"137","author":"Felner","year":"2000","unstructured":"12. Felner EI, Thompson MT, Ratliff AF, White PC, Dickson BA. Time course of recovery of adrenal function in children treated for leukemia. J Pediatr 2000;137:21-24.","journal-title":"J Pediatr"},{"key":"ref12","doi-asserted-by":"publisher","unstructured":"13. Petersen KB, Jusko WJ, Rasmussen M, Schmiegelow K. Population pharmacokinetics of prednisolone in children with acute lymphoblastic leukemia. Cancer Chemother Pharmacol 2003;51:465-473. Epub 2003 Apr 16","DOI":"10.1007\/s00280-003-0602-3"},{"key":"ref13","doi-asserted-by":"publisher","first-page":"327","DOI":"10.1177\/00912709922007903","article-title":"DHEA and DHEA-S: a review","volume":"39","author":"Kroboth","year":"1999","unstructured":"14. Kroboth PD, Salek FS, Pittenger AL, Fabian TJ, Frye RF. DHEA and DHEA-S: a review. J Clin Pharmacol 1999;39:327-348.","journal-title":"J Clin Pharmacol"},{"key":"ref14","doi-asserted-by":"publisher","first-page":"23","DOI":"10.3803\/EnM.2017.32.1.23","article-title":"Acute Hyperglycemia Associated with Anti-Cancer Medication","volume":"32","author":"Hwangbo","year":"2017","unstructured":"15. Hwangbo Y, Lee EK. Acute Hyperglycemia Associated with Anti-Cancer Medication. Endocrinol Metab (Seoul) 2017;32:23-29.","journal-title":"Endocrinol Metab (Seoul)"},{"key":"ref15","doi-asserted-by":"publisher","first-page":"127","DOI":"10.1016\/S0140-6736(03)15264-6","article-title":"Persistence of impaired pancreatic beta-cell function in children treated for acute lymphoblastic leukaemia","volume":"363","author":"Mohn","year":"2004","unstructured":"16. Mohn A, Di Marzio A, Capanna R, Fioritoni G, Chiarelli F. Persistence of impaired pancreatic beta-cell function in children treated for acute lymphoblastic leukaemia. Lancet 2004;363:127-128.","journal-title":"Lancet"},{"key":"ref16","doi-asserted-by":"publisher","unstructured":"17. Oudin C, Berbis J, Bertrand Y, Vercasson C, Thomas F, Chastagner P, Ducassou S, Kanold J, Tabone MD, Paillard C, Poir\u00e9e M, Plantaz D, Dalle JH, Gandemer V, Thouvenin S, Sirvent N, Saultier P, B\u00e9liard S, Leverger G, Baruchel A, Auquier P, Pannier B, Michel G. Prevalence and characteristics of metabolic syndrome in adults from the French childhood leukemia survivors' cohort: a comparison with controls from the French population. Haematologica 2018;103:645-654. Epub 2018 Jan 19","DOI":"10.3324\/haematol.2017.176123"},{"key":"ref17","doi-asserted-by":"publisher","unstructured":"18. Nottage KA, Ness KK, Li C, Srivastava D, Robison LL, Hudson MM. Metabolic syndrome and cardiovascular risk among long-term survivors of acute lymphoblastic leukaemia - From the St. Jude Lifetime Cohort. Br J Haematol 2014;165:364-374. Epub 2014 Jan 27","DOI":"10.1111\/bjh.12754"},{"key":"ref18","doi-asserted-by":"publisher","unstructured":"19. Gordijn MS, van Litsenburg RR, Gemke RJ, Bierings MB, Hoogerbrugge PM, van de Ven PM, Heijnen CJ, Kaspers GJ. Hypothalamic-pituitary-adrenal axis function in survivors of childhood acute lymphoblastic leukemia and healthy controls. Psychoneuroendocrinology 2012;37:1448-1456. Epub 2012 Mar 2","DOI":"10.1016\/j.psyneuen.2012.01.014"},{"key":"ref19","doi-asserted-by":"publisher","first-page":"1139","DOI":"10.1152\/physrev.00020.2012","article-title":"11\u03b2-hydroxysteroid dehydrogenases: intracellular gate-keepers of tissue glucocorticoid action","volume":"93","author":"Chapman","year":"2013","unstructured":"20. Chapman K, Holmes M, Seckl J. 11\u03b2-hydroxysteroid dehydrogenases: intracellular gate-keepers of tissue glucocorticoid action. Physiol Rev 2013;93:1139-1206.","journal-title":"Physiol Rev"},{"key":"ref20","doi-asserted-by":"publisher","first-page":"1305","DOI":"10.1210\/endo.138.3.4994","article-title":"Immunodetection of 11 beta-hydroxysteroid dehydrogenase type 2 in human mineralocorticoid target tissues: evidence for nuclear localization","volume":"138","author":"Shimojo","year":"1997","unstructured":"21. Shimojo M, Ricketts ML, Petrelli MD, Moradi P, Johnson GD, Bradwell AR, Hewison M, Howie AJ, Stewart PM. Immunodetection of 11 beta-hydroxysteroid dehydrogenase type 2 in human mineralocorticoid target tissues: evidence for nuclear localization. Endocrinology 1997;138:1305-1311.","journal-title":"Endocrinology"},{"key":"ref21","doi-asserted-by":"publisher","unstructured":"22. Sai S, Nakagawa Y, Yamaguchi R, Suzuki M, Sakaguchi K, Okada S, Seckl JR, Ohzeki T, Chapman KE. Expression of 11beta-hydroxysteroid dehydrogenase 2 contributes to glucocorticoid resistance in lymphoblastic leukemia cells. Leuk Res 2011;35:1644-1648. Epub 2011 Jul 26","DOI":"10.1016\/j.leukres.2011.07.002"},{"key":"ref22","doi-asserted-by":"publisher","unstructured":"23. Cohen JB, Geara AS, Hogan JJ, Townsend RR. Hypertension in Cancer Patients and Survivors: Epidemiology, Diagnosis, and Management. JACC CardioOncol 2019;1:238-251. Epub 2019 Dec 17","DOI":"10.1016\/j.jaccao.2019.11.009"},{"key":"ref23","doi-asserted-by":"publisher","first-page":"163","DOI":"10.1530\/eje.0.1490163","article-title":"Tissue-specific Cushing's syndrome, 11beta-hydroxysteroid dehydrogenases and the redefinition of corticosteroid hormone action","volume":"149","author":"Stewart","year":"2003","unstructured":"24. Stewart PM. Tissue-specific Cushing's syndrome, 11beta-hydroxysteroid dehydrogenases and the redefinition of corticosteroid hormone action. Eur J Endocrinol 2003;149:163-168.","journal-title":"Eur J Endocrinol"},{"key":"ref24","doi-asserted-by":"publisher","unstructured":"25. Goodwin JE, Geller DS. Glucocorticoid-induced hypertension. Pediatr Nephrol 2012;27:1059-1066. Epub 2011 Jul 9","DOI":"10.1007\/s00467-011-1928-4"},{"key":"ref25","doi-asserted-by":"publisher","unstructured":"26. Al-Hashmi S, Boels PJ, Zadjali F, Sadeghi B, S\u00e4llstr\u00f6m J, Hultenby K, Hassan Z, Arner A, Hassan M. Busulphan-cyclophosphamide cause endothelial injury, remodeling of resistance arteries and enhanced expression of endothelial nitric oxide synthase. PLoS One 2012;7:e30897. Epub 2012 Jan 27","DOI":"10.1371\/journal.pone.0030897"},{"key":"ref26","doi-asserted-by":"publisher","unstructured":"27. Bhandari SK, Batech M, Shi J, Jacobsen SJ, Sim JJ. Plasma renin activity and risk of cardiovascular and mortality outcomes among individuals with elevated and nonelevated blood pressure. Kidney Res Clin Pract 2016;35:219-228. Epub 2016 Jul 26","DOI":"10.1016\/j.krcp.2016.07.004"},{"key":"ref27","doi-asserted-by":"publisher","first-page":"324","DOI":"10.1111\/j.1365-2265.2007.02898.x","article-title":"Diagnosis and treatment of low-renin hypertension","volume":"67","author":"Mulatero","year":"2007","unstructured":"28. Mulatero P, Verhovez A, Morello F, Veglio F. Diagnosis and treatment of low-renin hypertension. Clin Endocrin (Oxf) 2007;67:324-334.","journal-title":"Clin Endocrin (Oxf)"},{"key":"ref28","doi-asserted-by":"publisher","first-page":"728","DOI":"10.4103\/2230-8210.100665","article-title":"Low renin hypertension","volume":"16","author":"Sahay","year":"2012","unstructured":"29. Sahay M, Sahay RK. Low renin hypertension. Indian J Endocrinol Metab 2012;16:728-739.","journal-title":"Indian J Endocrinol Metab"},{"key":"ref29","doi-asserted-by":"publisher","unstructured":"30. Baskar R, Lee KA, Yeo R, Yeoh KW. Cancer and radiation therapy: current advances and future directions. Int J Med Sci 2012;9:193-199. Epub 2012 Feb 27","DOI":"10.7150\/ijms.3635"},{"key":"ref30","unstructured":"31. Hutnik M, Wygoda A, Sk\u0142adowski K, Rutkowski T, Pilecki B. Dawki tolerancji dla narz\u0105d\u00f3w krytycznych w radioterapii chorych na raka g\u0142owy i szyi. Nowotwory Journal of Oncology 2013;1:35-47."},{"key":"ref31","doi-asserted-by":"publisher","first-page":"2761","DOI":"10.1210\/jc.2018-01175","article-title":"Hypothalamic-Pituitary and Growth Disorders in Survivors of Childhood Cancer: An Endocrine Society Clinical Practice Guideline","volume":"103","author":"Sklar","year":"2018","unstructured":"32. Sklar CA, Antal Z, Chemaitilly W, Cohen LE, Follin C, Meacham LR, Murad MH. Hypothalamic-Pituitary and Growth Disorders in Survivors of Childhood Cancer: An Endocrine Society Clinical Practice Guideline. J Clin Endocrinol Metab 2018;103:2761-2784.","journal-title":"J Clin Endocrinol Metab"}],"container-title":["Journal of Clinical Research in Pediatric Endocrinology"],"original-title":[],"deposited":{"date-parts":[[2024,7,26]],"date-time":"2024-07-26T13:04:36Z","timestamp":1721999076000},"score":1,"resource":{"primary":{"URL":"https:\/\/jcrpe.org\/jvi.aspx?un=JCRPE-50023"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2022,12,1]]},"references-count":32,"journal-issue":{"issue":"4","published-online":{"date-parts":[[2022,12,1]]}},"URL":"https:\/\/doi.org\/10.4274\/jcrpe.galenos.2022.2022-2-2","relation":{},"ISSN":["1308-5727","1308-5735"],"issn-type":[{"value":"1308-5727","type":"print"},{"value":"1308-5735","type":"electronic"}],"subject":[],"published":{"date-parts":[[2022,12,1]]}}}